Amgen Inc. Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31)
Amgen Inc. (AMGN) reported Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31) of $1.60 billion for the 6-month period ending 2014-06-30, per its 10-Q filed 2014-08-05.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount · last filed 2014-08-05
- Amgen Inc. stock repurchase program, remaining authorized repurchase amount (deprecated 2014-01-31) for the quarter ending 2014-06-30 was $0.00, a 100.00% decline year-over-year.
- Amgen Inc. stock repurchase program, remaining authorized repurchase amount (deprecated 2014-01-31) for the quarter ending 2014-03-31 was $1.60B, a 0.00% change year-over-year.
- Amgen Inc. stock repurchase program, remaining authorized repurchase amount (deprecated 2014-01-31) for the quarter ending 2013-12-31 was $0.00, a 100.00% decline year-over-year.
- Amgen Inc. stock repurchase program, remaining authorized repurchase amount (deprecated 2014-01-31) for the quarter ending 2013-09-30 was -$1.60B.
- Amgen Inc. stock repurchase program, remaining authorized repurchase amount (deprecated 2014-01-31) for fiscal 2013 was $1.60B, a 30.43% decline from fiscal 2012.
- Amgen Inc. stock repurchase program, remaining authorized repurchase amount (deprecated 2014-01-31) for fiscal 2012 was $2.30B.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31) 1 month | Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31) 3 month | Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31) 6 month | Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31) 9 month | Stock Repurchase Program, Remaining Authorized Repurchase Amount (Deprecated 2014-01-31) 12 month |
|---|---|---|---|---|---|
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $1.60B 10-Q · filed 2014-08-05 | $1.60B derived: sum of 3 quarters · filed 2014-08-05 | $0.00 derived: sum of 4 quarters · filed 2014-08-05 | |
| 2014-03-31 | $1.60B 10-Q · filed 2014-04-30 | $1.60B derived: sum of 2 quarters · filed 2014-04-30 | $0.00 derived: sum of 3 quarters · filed 2014-04-30 | $1.60B derived: sum of 4 quarters · filed 2014-04-30 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-24 | -$1.60B derived: sum of 2 quarters · filed 2014-02-24 | $0.00 derived: sum of 3 quarters · filed 2014-02-24 | $1.60B 10-K · filed 2014-02-24 | |
| 2013-09-30 | -$1.60B derived: 10-K 12 month − 3 quarters · filed 2014-02-24 | $0.00 derived: sum of 2 quarters · filed 2014-02-24 | $1.60B 10-Q · filed 2013-10-29 | $2.30B derived: sum of 4 quarters · filed 2014-02-24 | |
| 2013-06-30 | $1.60B 10-Q · filed 2013-08-06 | $3.20B derived: sum of 2 quarters · filed 2013-08-06 | $3.90B derived: sum of 3 quarters · filed 2013-08-06 | $3.10B derived: sum of 4 quarters · filed 2013-08-06 | |
| 2013-03-31 | $1.60B 10-Q · filed 2013-05-03 | $2.30B derived: sum of 2 quarters · filed 2013-05-03 | $1.50B derived: sum of 3 quarters · filed 2013-05-03 | $300.00M derived: sum of 4 quarters · filed 2013-05-03 | |
| 2012-12-31 | $700.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | -$100.00M derived: sum of 2 quarters · filed 2013-02-27 | -$1.30B derived: sum of 3 quarters · filed 2013-02-27 | $2.30B 10-K · filed 2013-02-27 | |
| 2012-09-30 | -$800.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | -$2.00B derived: sum of 2 quarters · filed 2012-11-06 | $1.60B 10-Q · filed 2012-11-06 | ||
| 2012-06-30 | -$1.20B derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $2.40B 10-Q · filed 2012-08-08 | |||
| 2012-03-31 | $3.60B 10-Q · filed 2012-05-08 | ||||
| 2011-12-31 | $5.00B 10-K · filed 2012-02-29 | ||||
| 2011-10-31 | $10.00B 10-K · filed 2012-02-29 | ||||
| 2011-10-13 | $10.00B 10-Q · filed 2011-11-04 | ||||
| 2011-06-30 | $6.40B 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |